49 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
RGNX REGENXBIO Inc. $70.3974 $2.27B N/A
Article Searches
REGENXBIO, Inc. (RGNX) CEO Kenneth Mills on Q3 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4302900-regenxbio-inc-rgnx-ceo-kenneth-mills-q3-2019-results-earnings-call-transcript?source=feed_sector_healthcare Nov 05, 2019 - REGENXBIO, Inc. (NASDAQ:RGNX) Q3 2019 Earnings Conference Call November 5, 2019 04:30 PM ET Company Participants Patrick Christmas - Senior Vice President and General Counsel Kenneth Mills - President
Regenxbio Inc. (RGNX) Q3 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/11/05/regenxbio-inc-rgnx-q3-2019-earnings-call-transcrip.aspx?source=iedfolrf0000001 Nov 05, 2019 - RGNX earnings call for the period ending September 30, 2019.
Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates http://www.zacks.com/stock/news/605253/regenxbio-rgnx-reports-q3-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-605253 Nov 05, 2019 - Regenxbio (RGNX) delivered earnings and revenue surprises of -3.30% and 97.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA http://www.zacks.com/stock/news/565788/ultragenyxs-rare-nda-for-lc-faod-drug-accepted-by-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-565788 Oct 15, 2019 - Ultragenyx (RARE) announces FDA's acceptance of the NDA for UX007 for the treatment of LC-FAOD.
Big Pharma Has Mad Love For These 2 Biotechs https://www.fool.com/investing/2019/10/11/big-pharma-has-mad-love-for-these-2-biotechs.aspx?source=iedfolrf0000001 Oct 11, 2019 - These companies' collaborations with bigger businesses validates their science -- and paves the way for future revenues and profits.
Wet AMD Space in Focus: New Drug Approvals & Key Advancements http://www.zacks.com/stock/news/557772/wet-amd-space-in-focus-new-drug-approvals-key-advancements?cid=CS-ZC-FT-analyst_blog|industry_focus-557772 Oct 10, 2019 - The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.
Ultragenyx Gets FDA Approval for Label Expansion of Crysvita http://www.zacks.com/stock/news/545745/ultragenyx-gets-fda-approval-for-label-expansion-of-crysvita?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-545745 Oct 02, 2019 - Ultragenyx (RARE) and partner Kyowa Kirin get FDA approval for the label expansion of Crysvita in pediatric patients with X-linked hypophosphatemia.
Ultragenyx-GeneTx Get Orphan Drug Status for GTX-102 From FDA http://www.zacks.com/stock/news/501422/ultragenyx-genetx-get-orphan-drug-status-for-gtx-102-from-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-501422 Sep 04, 2019 - The FDA grants Orphan Drug and Rare Pediatric Disease designations to Ultragenyx (RARE) and partner GeneTx Biotherapeutics' GTX-102 for the treatment of Angelman Syndrome.
Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio https://www.fool.com/investing/2019/05/24/approval-of-a-game-changing-gene-therapy-for-sma-d.aspx?source=iedfolrf0000001 May 24, 2019 - A $2.1 million price tag could make Zolgensma a blockbuster medicine for these companies.
Regenxbio, Inc. (RGNX) CEO Kenneth Mills on Q1 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4261299-regenxbio-inc-rgnx-ceo-kenneth-mills-q1-2019-results-earnings-call-transcript?source=feed_sector_healthcare May 07, 2019 - Regenxbio, Inc. (NASDAQ:RGNX) Q1 2019 Earnings Conference Call May 07, 2019, 16:30 ET Company Participants Patrick Christmas - SVP & General Counsel Kenneth Mills - CEO, President & Director S

Pages: 12345

Page 1>